Cardiovascular Disease, Postmenopausal Vasomotor Symptoms
Conditions
Keywords
Postmenopausal vasomotor symptoms, Hot flush, Vascular function, Cardiac function, Cardiovascular risk factor
Brief summary
Recent large randomized, placebo-controlled studies assessing the health effects of HT question the overall benefits of long term HT, especially with respect to cardiovascular disease. However, recently menopausal women with severe hot flushes were mostly excluded from these trials. This was unfortunate since vasomotor symptoms may reflect different vascular sensitivity to estrogen or its deficiency, and therefore, the vascular responses to HT in women with and without hot flushes can differ. Aims of the present project are 1. to compare vascular, cardiac and sympathetic function in recently menopausal women with or without severe vasomotor symptoms 2. in a randomized placebo controlled clinical trial investigate vascular response to oral and trans-dermal HT.
Detailed description
We recruit 160 healthy postmenopausal women between ages 48-55. Eighty women must have severe vasomotor symptoms (at least seven severe or moderate hot flush attacks per day) whereas 80 comparators must be symptomless (no hot flushes). Thorough vascular function and risk factor assessments will be done, including clinical assessment of autonomic nervous system, endothelial function measurements, 24-hour ECG and blood pressure evaluation, and lipid and various other vascular surrogate marker measurements. In the first part of the study we compare these baseline measurements between women with or without severe vasomotor symptoms. In the second part of the study the women are randomized to receive placebo, oral estrogen, oral estrogen plus progestin or transdermal estrogen for 6 months. After the treatments the baseline assessments are repeated.
Interventions
2mg oral daily for 6 months
2mg E2 + 5mg MPA daily for 6 months
1 mg skin gel daily for 6 months
placebo daily for 6 months
Sponsors
Study design
Eligibility
Inclusion criteria
* Postmenopausal women between ages 48-55 * Minimum of 6 months and maximum of 36 months from last menstrual period * Postmenopausal status of these women will be confirmed by level of FSH that should exceed 30 U/l * Eighty women must have severe vasomotor symptoms (at least seven severe or moderate hot flush attacks per day) whereas eighty comparators must be symptomless
Exclusion criteria
* smoking * hysterectomy * dyslipidemia * overt hypertension (blood pressure \> 140/90) * diabetes * any regular medication * HT in the previous 3 months * body mass index over 27
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vascular function | 0 and 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac and sympathetic function | 0 and 6 months |
Countries
Finland